Albany – NY, Oct. 20, 2015 (GLOBE NEWSWIRE) — According to a new report published by Transparency Market Research Meningococcal Vaccines Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2022, the global meningococcal vaccines market was valued at USD 1.5 billion in 2013 and is expected to reach a value of USD 4.4 billion in 2022, growing at a CAGR of 12.4% from 2014 to 2022.
Browse the full Meningococcal Vaccines Market (Polysaccharide, Conjugate, Combination and Men B Vaccines, along with Pipeline Analysis) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2022 report at http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html
Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs sporadically throughout the world with seasonal variations. It accounts for a proportion of endemic bacterial meningitis, which can progress very rapidly leading to death within 24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in most of the cases. Five out of the several serogroups are known to cause meningococcal disease. The serogroups responsible for causing the disease comprise A, B, C, Y and W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans and gets transmitted through droplet inhalation by means of close contact such as exposure to smokers, crowded living conditions such as dormitories, certain inherited disorders of the immune system, functional/anatomical asplenia or through intimate oral contact among others. According to the European Federation of Pharmaceutical Industries and Association, every year, meningitis affects almost 500,000 people globally, primarily affecting toddlers, infants and young adults, due to weaker immune system.
The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate, combination and Men B vaccines. The report also provides analysis for vaccine under development, NmVac4-DT by JN- International that is expected to be commercialized during the forecast period 2014 to 2022. The vaccine types are further segmented by different brands available in the market. The conjugate vaccines segment is likely to lead the overall meningococcal vaccines market in terms of revenue, which is estimated to be worth USD 3,127.2 million by 2022 at a CAGR of 11.1%. According to Department of Health, U.K., Bexsero is the first serogroup B vaccine to be incorporated into the national immunization program and is expected to be available in the market for sales post settle of price negotiations. The U.S. FDA recently approved two Men B vaccines: Trumenba by Pfizer in October 2014 and Bexsero by Novartis in January 2015.
The market for meningococcal vaccines is largely driven by increasing government intervention in reforming the healthcare infrastructure and incorporation of legislations specific to meningococcal vaccination. The public-private partnerships for conducting research and development, and manufacturing of quality vaccines at an affordable price are also contributing positively in driving market growth. Awareness campaigning from government and non-profit organizations, and obligatory immunization for individuals heading to Mecca (for Hajj pilgrimage) and the South African meningitis belt will also contribute to growth of this market. High cost of few but vital vaccines, such as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of the vaccine are expected to be some of the major factors posing a challenge to the adequate uptake of these vaccines.
The key players dominating the global meningococcal vaccines market include Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players account for more than 90% of the meningococcal vaccines market. Players such as Serum Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron Biotech and Baxter account for the remaining market share.
The global meningococcal vaccines market is segmented as follow:
Meningococcal Vaccines Market, by Type
- Polysaccharide Vaccines, by Brand
- Quadri Meningo
- Bi Meningo
- Conjugate Vaccines, by Brand
- Combination Vaccines, by Brand
- Men B Vaccines, by Brand
Meningococcal Vaccines Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Rest of the World
- Latin America
- Rest of RoW
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
CONTACT: Mr. Nachiket Ghumare 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: firstname.lastname@example.org Website: http://www.transparencymarketresearch.com